Insights Into Treatment Pathways of Hodgkin Lymphoma 2021

Perspectives of community physicians from across the US on the management of classical Hodgkin lymphoma (cHL) with regard to clinical and nonclinical factors impacting treatment selection

Rocky Mountain Cancer Centers – October 14, 2021
Purchase Report

Faculty Chair

John M. Burke, MD

Rocky Mountain Cancer Centers, Colorado Springs, CO, USA

Texas Oncology – October 21, 2021
Purchase Report

Faculty Chair

Yair Levy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA

Cancer Center of Kansas – October 26, 2021
Purchase Report

Faculty Chair

John M. Burke, MD

Rocky Mountain Cancer Centers, Colorado Springs, CO, USA

East – October 28, 2021
Purchase Report

Faculty Chair

Yair Levy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA

More Information

  • Virtual series

More Information

  • Live Meeting

More Information

  • Virtual series

More Information

  • Virtual series

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Assess advisors’ current management of cHL
  • Gain insights into advisors’ perceptions of available therapies and understanding of data
  • Understand impact of pathways and other nonclinical factors that may affect treatment selection

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.